Glomerulonephritis: all 115 studies

Page 1 of 2. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingNCT07902817Phase 3
• China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational StudyRecruitingNCT07783737
• Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyRecruitingNCT07746895Phase 4
• A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA NephropathyNot yet recruitingNCT07642050Phase 3
• A Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingNCT07541287Phase 2
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 3
• Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe ProteinuriaNot yet recruitingNCT07431931Not applicable
• The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.RecruitingNCT07330362
• PS-002 for the Treatment of IgA Nephropathy in AdultsRecruitingNCT07182227Phase 1/2
• Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous NephropathyNot yet recruitingNCT07096986Phase 2
• Study of BHV-1400 in IgA NephropathyRecruitingNCT07054684Phase 1
• Atacicept in Multiple Glomerular DiseasesRecruitingNCT06983028Phase 2
• The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in FinlandRecruitingNCT06889948Phase 2
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 3
• Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)RecruitingNCT06821919
• Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics StudyNot yet recruitingNCT06792448
• Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?RecruitingNCT06676384Phase 4
• Using Renal Elastography Measurements for Evaluation of Glomerulonephritis PatientsNot yet recruitingNCT06623877Not applicable
• Obinutuzumab in Treatment of Fibrillary GlomerulonephritisRecruitingNCT06295770Phase 2
• Affection of Renal and Urinary System in IBD PatientsNot yet recruitingNCT06249243
• Assessment of the Association Between Metabolic Associated Fatty Liver Disease (MFLD) and Biopsy Proved Cases of GNRecruitingNCT06157125
• Rescue of Nephrons With ALE.F02 (RENAL-F02)RecruitingNCT06047171Phase 2
• A Study of Rituximab in Frontline Therapy for GlomerulonephritisRecruitingNCT05761938
• Correlation and Clinical Utility of Urinary Biomarker in Membranous GlomerulonephritisRecruitingNCT05688865
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat GlomerulonephritisRecruitingNCT05517980Phase 2
• China Kidney Patient Trials NetworkRecruitingNCT05036850
• A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyRecruitingNCT04663204Phase 2
• Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.RecruitingNCT04662723Phase 4
• Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in ChildrenRecruitingNCT04654507Phase 3
• Detection of Renal Fibrosis and Prediction of Kidney Function DeclineRecruitingNCT04625140
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyRecruitingNCT04557462Phase 3
• Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal CenterEnrolling by invitationNCT01016613
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedNCT05834738Phase 2Results posted
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)TerminatedNCT04564339Phase 2Results posted
• Safety and Efficacy Study of VIS649 for IgA NephropathyCompletedNCT04287985Phase 2Results posted
• Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not TransplantedCompletedNCT03832114Phase 2Results posted
• Adrenocorticotropic Hormone in Membranous NephropathyCompletedNCT03025828Phase 4Results posted
• Efficacy and Safety of Atacicept in IgA NephropathyTerminatedNCT02808429Phase 2Results posted
• Pilot Study of Rituximab to Treat Fibrillary GlomerulonephritisCompletedNCT02197767Phase 2Results posted
• Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 3Results posted
• Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous GlomerulonephritisCompletedNCT00843856Phase 4Results posted
• Abatacept and Cyclophosphamide Combination Therapy for Lupus NephritisCompletedNCT00774852Phase 2Results posted
• Rituxan in Churg Strauss Syndrome With Renal InvolvementTerminatedNCT00424749Phase 2Results posted
• Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional DataActive, not recruitingNCT07741552
• Telitacicept for PGNMID: A Single-Arm StudyActive, not recruitingNCT07111338Phase 2
• Effect of Finerenone in Patients With Non-diabetic GlomerulonephritisCompletedNCT06835322Phase 2
• ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASESCompletedNCT06753942
• Two Anti-CD20 Regimens for Fibrillary GlomerulonephritisCompletedNCT06680349Phase 4
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Active, not recruitingNCT06564142Phase 3
• KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisTerminatedNCT06342960Phase 1/2
• Effect of Ramadan Fasting on Kidney Function and Proteinuria in Patients With GlomerulonephritisCompletedNCT06327009
• Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNTerminatedNCT06209736Phase 2
• KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisTerminatedNCT05938725Phase 1/2
• A Study of Zigakibart in Adults With IgA NephropathyActive, not recruitingNCT05852938Phase 3
• A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)TerminatedNCT05810961Phase 2
• A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)CompletedNCT05810948Phase 2
• Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune DepositsActive, not recruitingNCT05654506Phase 2
• A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy PatientsStatus unknownNCT05546047Phase 4
• Study of HRS-5965 in Healthy Subjects and Subjects With Renal InsufficiencyCompletedNCT05505955Phase 1
• TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325
• Bortezomib for Treating Glomerular DiseasesStatus unknownNCT05383547Not applicable
• Empagliflozin in Patients With GlomerulonephritisCompletedNCT05283057Phase 3
• A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background TherapyCompletedNCT05174221Phase 1
• An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney DiseasesTerminatedNCT04950114Phase 2
• PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VCompletedNCT04870333Phase 2/3
• Causes and Prevention of Thromboembolic Disease in Nephrotic SyndromeCompletedNCT04850378Phase 1/2
• Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2Status unknownNCT04846010Phase 1/2
• Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)CompletedNCT04733040Phase 2
• US Time-Harmonic Elastography for the Early Detection of Childhood GlomerulonephritisStatus unknownNCT04582890
• Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Phase 3
• Global Kidney Patient Trials NetworkCompletedNCT04389827
• A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseTerminatedNCT04387448Phase 2
• Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to GlomerulonephritisStatus unknownNCT04349683Phase 4
• Urinary T Cell Biomarker for Prediction in Lupus NephritisStatus unknownNCT04320797
• Urinary T Cell Biomarker for Prediction in ANCA GlomerulonephritisStatus unknownNCT04320667
• Plant Versus Animal Dietary Protein and the Effect on ProteinuriaStatus unknownNCT04058951Not applicable
• FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy SubjectsCompletedNCT03970122Phase 1
• Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With CystinuriaCompletedNCT03836144
• Synergetic B-cell Immunomodulation in SLE - 2nd Study.CompletedNCT03747159Phase 3
• The Canadian Glomerulonephritis Registry and Translational Research InitiativeStatus unknownNCT03460054
• Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1Status unknownNCT03357653Phase 3
• Acute Post Streptococcal GlomerulonephritisStatus unknownNCT03184103
• Predictors of Disease Progression in Primary Focal Segmental GlomerulosclerosisCompletedNCT03126201
• Immunoadsorption in Anti-GBM Glomerulonephritis.CompletedNCT02765789Not applicable
• Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA NephropathyStatus unknownNCT02765594Phase 4
• Recurrent Glomerulonephritis After Renal TransplantationCompletedNCT02700516
• Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentTerminatedNCT02523768Phase 4
• ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudyStatus unknownNCT02155803Phase 2/3
• Efficacy and Safety of Shenyankangfu Tablets for Primary GlomerulonephritisStatus unknownNCT02063100Phase 4
• A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic SyndromeCompletedNCT01763580Phase 4
• An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus NephritisCompletedNCT01273389Phase 2
• Long-Acting Tacrolimus for the Treatment of Resistant Lupus NephritisCompletedNCT01206569Phase 4
• Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus NephritisCompletedNCT01203709Phase 4
• Aliskiren in Patients With Idiopathic Membranous NephropathyWithdrawnNCT01093781Not applicable
• A Dose Escalation Study of Long-acting ACTH Gel in Membranous NephropathyCompletedNCT01093157Phase 1/2
• The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous NephropathyCompletedNCT00983034Not applicable
• Aliskiren for Immunoglobulin A (IgA) NephropathyCompletedNCT00870493Phase 3
• Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After PyelonephritisStatus unknownNCT00868270
• Calcitriol in the Treatment of Immunoglobulin A NephropathyStatus unknownNCT00862693Phase 4
• Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) InhibitorCompletedNCT00437463Phase 3

← Glomerulonephritis overview